Showing 1 - 10 of 3,031
We describe the broad range of uncertainties faced by the developers of medical technologies. Empirically, we estimate the asset market incidence of two realizations of uncertainties we classify as within-market policy risks. The events we analyze concern the intellectual property of Myriad...
Persistent link: https://www.econbiz.de/10012457199
The past century witnessed a dramatic improvement in public health, the rise of modern medicine, and the transformation of the hospital from a fringe institution to one essential to the practice of medicine. In this paper, we explore how access to the hospital and modern medicine affects...
Persistent link: https://www.econbiz.de/10013462711
countries from 2000-2013. The World Trade Organization required its member countries to implement a minimum level of patent … protection within a specified time period as part of the TRIPS Agreement. However, members retained the right to impose price … product level, selection into TRIPS "treatment" is exogenously determined by compliance deadlines that vary across countries …
Persistent link: https://www.econbiz.de/10012457867
This paper contributes to the literature on innovation policies and institutional theory on conditions for effective institutional changes. The "three rights" reform of 26 universities and the mixed ownership reform of Southwest Jiaotong University are important explorations made by China in...
Persistent link: https://www.econbiz.de/10014247942
In the approaching era of genomic medicine, the underrepresentation of minority populations in human genetics and genomics research has raised growing concerns regarding the distributive justice in the translation of biomedical innovations into human health across populations. Quantitative...
Persistent link: https://www.econbiz.de/10013334374
We document the rise of China in offshore capital markets. Chinese firms use global tax havens to access foreign capital both in equity and bond markets. In the last twenty years, China's presence went from raising a negligible amount of capital in these markets to accounting for more than half...
Persistent link: https://www.econbiz.de/10013537759
This paper provides novel empirical evidence on the private value of patents and R&D in European firms during the period 1991-2004. We explore the relationship between firm's stock market value, patents, and "quality"-weighted patents issued by the European Patent Office (EPO) and the US Patent...
Persistent link: https://www.econbiz.de/10012465223
This paper examines three sets of explanations for variations in the strength of patent protection across sixty countries and a 150-year period. Wealthier nations are more likely to have patent systems, to allow patentees a longer time to put their patents into practice, and to ratify treaties...
Persistent link: https://www.econbiz.de/10012471298
Patent counts are very imperfect measures of innovative output. This paper discusses how additional data-the number of years a patent is renewed and the number of countries in which protection for the same invention is sought - can be used to improve on counts in studies which require a measure...
Persistent link: https://www.econbiz.de/10012473093
By thoroughly controlling for the country covariates, through a combination of matched sampling techniques with fixed-effect panel regression models, the analyses arrive at robust results across the various model specifications. First, national pharmaceutical patent protection alone does not...
Persistent link: https://www.econbiz.de/10012462357